Connect
← Return to What is the recommended treatment after 6 Pluvicto doses?
Discussion
What is the recommended treatment after 6 Pluvicto doses?
Prostate Cancer | Last Active: Dec 19, 2023 | Replies (27)Comment receiving replies
Going on 8 years Advanced pCA. Exhausted all other options, Hormone therapy and Docetaxel / Cabazitaxel Chemo. Making arrangements to get Pluvicto as it just got to my small city. I will be the first locally to get it. Not sure if I want to delay or not as the precautions for the radioactivity are pretty serious for 1 week. Basically isolation. I feel pretty well with not much pain. lower back occasionally hurts but walking around helps.
I was lucky to get a research professor at the Huntsman Cancer Institute in Salt Lake City for my first doctor. He put me on a Hormone therapy clinical trial with TAK 700. It worked for almost 4 years.
He conducted the Talapro-2 study of a combination of 2 drugs. At first it was just for people who had a defective prostate repair gene, but now he has seen some benefit in all levels of pCA. This may be the next step for me after Pluvicto or if I delay Pluvicto. Check out the Talapro-2 study.
Replies to "Going on 8 years Advanced pCA. Exhausted all other options, Hormone therapy and Docetaxel / Cabazitaxel..."
Connect
Urology times Combining the novel agent TAK-700 with androgen-deprivation therapy (ADT) led to a numerical but not statistically significant improvement in overall survival (OS) versus ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), according to findings from the phase 3 SWOG S1216 trial. Despite missing the primary end point, a posthoc analysis uncovered a pathway for optimizing care in this patient population.1
The findings, which were presented at the 2021 ASCO Annual Meeting, showed that at a median follow-up of 4.9 years, the median OS was 81.1 months in the TAK-700 arm versus 70.2 months in the control arm (HR, 0.86; 95% CI, 0.72-1.02; P = .04). This 11+ month improvement in OS did not meet the trial’s prespecified criteria for statistical significance.